A Study to Evaluate the Efficacy and Safety of MG-K10 in Participants Who Have Atopic Dermatitis

NCT07479615 | Not Yet Recruiting Phase 3 DMC FDA Drug

• 1 other identifier: MG-K10-AD-202
• Study Type: interventional
• Target: 498
• Locations: 0 countries
• Sites: N/A

Brief Summary

Rationale (What is the reason for this study?) Atopic dermatitis (AD) is a condition that makes the skin dry and itchy and is the most common skin condition that causes redness and irritation. The exact cause of AD is unclear but genetic and environmental factors are believed to play a role. Common treatment options for participants with AD include basic skin care, medicine that is applied to the skin, and medicine that works in more than one part of the body. Typically, these treatment options work for participants with AD but some have skin lesions (skin sores or damaged skin) over large areas of the body and do not see an improvement in their AD symptoms. MG-K10 has been shown to be effective in treating participants with moderate-to-severeatopic dermatitis in Phase 2 studies (Chaoying Gu et al.2025) and has already completed a Phase 3 clinical study for adults in China. This study aims to evaluate the efficacy and safety of MG-K10 in the adolenscents and adults with moderate-to-severeatopic dermatitis in global population. Objectives (goals of the study) and Endpoints (how goals are measured) Check how MG-K10 treatment affects atopic dermatitis Study doctors will look at the safety of MG-K10 and if any side effects are reported by participants when they take it. Check how the body processes MG-K10 Check how MG-K10 affects the biomarkers of effect Check how the body's immune system (the body's defense system) reacts to MG-K10

Conditions

Atopic Dermatitis; Atopic Eczema

Outcome Measures

Primary Outcomes (1)

• To evaluate the efficacy of MG K10 monotherapy compared to placebo in adults and adolescents with moderate to severe atopic dermatitis (AD).

  Proportion of participants with EASI 75

  From baseline (D1) to 60 week

Study Arms (2)

MG-K10 Humanized Monoclonal Antibody Injection

EXPERIMENTAL

After W16 patients will be re-randomize to: 1. MG-K10 Humanized Monoclonal Antibody Injection for responder Q4W 2. MG-K10 Humanized Monoclonal Antibody Injection for responder Q8W 3. Placebo Injection for responder Q4W 4. MG-K10 Humanized Monoclonal Antibody Injection for non-responder Q4W

Biological: MG-K10 Humanized Monoclonal Antibody Injection

Placebo group:

PLACEBO COMPARATOR

After W16 patients will be re-randomize to: MG-K10 Humanized Monoclonal Antibody Injection Q4W

Biological: MG-K10 Humanized Monoclonal Antibody Injection

Interventions

MG-K10 Humanized Monoclonal Antibody Injection BIOLOGICAL

MG-K10 Humanized Monoclonal Antibody Injection

MG-K10 Humanized Monoclonal Antibody Injection; Placebo group:

Eligibility Criteria

• Age: 12 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Age: ≥12 years, both males and females.
• Diagnosed with AD (according to the 2014 American Academy of Dermatology Consensus Criteria) that has been present for ≥1 year before the screening visit, and meeting the following conditions:
• Within 6 months prior to the screening visit, the patient has shown an insufficient response to topical medication or is medically unsuitable for topical treatment (e.g., significant side effects or safety risks).
• Participants should start a stable dose of moisturizer from the signing of ICF, apply a moisturizer twice daily for at least 7 consecutive days prior to randomization and continue using it throughout the study period.
• Women of childbearing age have a negative blood pregnancy test result during the screening period.
• Participants and their partners agree to use effective contraception from the time of signing the Informed Consent Form (ICF) until 6 months after the end of treatment ; no donation or freezing of germ cells is allowed from the time of signing the ICF until 6 months after the end of treatment.
• The participant voluntarily signs the ICF and can comply with all required visits and study-related procedures outlined in the protocol.
• For participants ≥ 12 and \< 18 years of age at Screening Visit: Parent or legal guardian, as required, has voluntarily signed and dated an informed consent form, approved by an IEC, after the nature of the stud has been explained and the participant's parent or legal guardian has had the opportunity to ask questions.

You may not qualify if:

• Body weight \< 30 kilograms (kg).
• The participant currently has a diagnosis of another active skin disease that may affect AD evaluation (e.g., psoriasis or lupus erythematosus).
• Known allergies to any component of the investigational drug.
• The participant cannot tolerate venipuncture or have a history of needle or blood phobia.
• The participant has comorbidities that may require systemic steroid therapy, other intervention measures, or require active and frequent monitoring.
• Those with significant cardiac, pulmonary, gastrointestinal, hepatic, renal, hematologic, neurologic, and psychiatric disorders that are unstable or not well controlled and are considered clinically significant by the investigator.
• Participants with ocular diseases deemed unsuitable for study entry by the investigator, such as a history of atopic keratoconjunctivitis involving the cornea.
• Participants are planning to undergo major surgery during the study period, including inpatient and outpatient surgeries.
• Patients with malignant tumors within 5 years
• Participants with any of the following conditions within the related timeline:
• Use of biologics
• Use of targeted inhibitors (e.g., JAK inhibitors), systemic corticosteroids, cyclosporine, or other immunosuppressants
• Use of topical treatments for AD
• Receipt of allergen-specific immunotherapy
• Vaccination with live or attenuated live vaccines

Sponsors & Collaborators

• Shanghai Mabgeek Biotech.Co.Ltd: lead

MeSH Terms

Conditions

Dermatitis, Atopic

Condition Hierarchy (Ancestors)

Skin Diseases, Genetic; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Dermatitis; Skin Diseases; Skin and Connective Tissue Diseases; Skin Diseases, Eczematous; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases

Central Study Contacts

Yunfei Xia

CONTACT

+86 021-51371305; yunfei.xia@mabgeek.com

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 11, 2026
• First Posted: March 18, 2026
• Study Start: May 1, 2026
• Primary Completion (Estimated): January 1, 2029
• Study Completion (Estimated): January 1, 2029
• Last Updated: March 18, 2026

Record last verified: 2026-03

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL